/Join_Us.gif)
/Morrison_Foerster.gif)
/Clinical_trial_470_x_80_(new).gif)
Clinical Trials Update provides you with latest news about clinical trials conducted by MVA member companies. The update gives insight to progress in studies, results and possible indications.
NeuroSearch Announces Positive Key Results from Phase II Study with ABT-894 in Adults with ADHD
20 June - NeuroSearch reports positive results from a Phase II study with ABT-894, a neuronal nicotinic receptor (NNR) modulator, for the treatment of adults suffering from Attention-Deficit Hyperactivity Disorder (ADHD). Results from the Phase II study show that ABT-894 was efficacious in adult ADHD measured as a statistically significant improvement on the primary endpoint; the total score of the Conners' Adult ADHD Rating Scales (CAARS).
Bavarian Nordic Reports Interim Data From Phase I/II Studies With Breast Cancer Vaccine
19 June - Bavarian Nordic's cancer research unit, BN ImmunoTherapeutics, has completed an interim analysis of its first two clinical studies with MVA-BN(R)-HER2, a cancer vaccine immunotherapy for breast cancer patients. These preliminary data show that MVA-BN(R)-based, HER2 directed vaccination is a biologically active treatment for patients with HER2 positive breast cancer. The final study data are expected around the turn of the year 2008/2009.
ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb Schizophrenia Trial
16 June - ACADIA Pharmaceuticals have announced results from its Phase IIb trial with ACP-104 for the treatment of schizophrenia. The study did not meet its primary endpoint of antipsychotic efficacy or any of the secondary endpoints. Neither dose of ACP-104 demonstrated improved efficacy as compared to placebo.
